Detalhe da pesquisa
1.
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8. 7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
Eur. heart j;
42(31): 2995-3007, Aug. 2021. graf, tab
Artigo
em Inglês
| CONASS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1292869
2.
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin / Desfechos cardiovasculares semelhantes em pacientes com diabetes e risco estabelecido ou alto para doença vascular coronariana tratada com dulaglutida com e sem linha de base metformina
Eur. heart j;
42(26): 1-9, July. 2021. graf., tab.
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1145686
3.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Lancet;
394(10193): 131-138, Jul. 2019. graf, tab
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1046322
4.
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
Heart;
104(15): 1292-1299, Aug. 2018. graf, tab
Artigo
em Inglês
| SES-SP, CONASS, SESSP-IDPCPROD, SES-SP | ID: biblio-1223857
5.
Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE 3 Trial
Journal of the American Heart Association;
7(15): 008918, July. 2018. tab, graf
Artigo
em Inglês
| SES-SP, CONASS, SESSP-IDPCPROD, SES-SP | ID: biblio-1224109
6.
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
Lancet;
388(10050): 1161-1169, 2016.
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1064592
7.
Apixaban in patients with atrial fibrillation
N. Engl. j. med;
364(9): 806-817, 2011. ilus, tab
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1064869